

# NWT Clinical Practice Information Notice

UPON RECEIPT: (1) PLEASE FOLLOW THE DIRECTIONS BELOW  
 (2) FILE THIS NOTICE IN SECTION C, CLINICAL PRACTICE INFORMATION BINDER FOR FUTURE REFERENCE

The following clinical practice has been approved for use in the Northwest Territories Health and Social Services system, and has been distributed to:

Hospitals     
  Community Health Centers     
  Public Health Units     
  Doctors' Offices     
  Social Services Offices     
  Other: \_\_\_\_\_

The information contained in this document is a Departmental:

Policy     
  Standard     
  Protocol     
  Procedure     
  Guidelines

**Title: Access to Human Papillomavirus vaccine (Gardasil™)**  
**Effective Date: November 23, 2006**

Health Canada has recently licensed a new vaccine against human papillomavirus (HPV). This vaccine, called *Gardasil™*, is designed to prevent HPV 6, 11, 16 & 18 related cervical cancer, cervical dysplasias, vulvar or vaginal dysplasias, or genital warts.


HPV is recognized as a causative agent of cervical cancer (Canada Communicable Disease Report, Volume 32S1, July 2006). The virus also causes anogenital warts in both sexes and is associated with anal cancer and cancer of the vulva, vagina and penis. Based on studies to-date its efficacy range is between 90 to 100 percent against the 4 serotypes of HPV included in the vaccine.

*Gardasil™* is a prophylactic vaccine. It is best given to HPV-naïve women and is approved for use in girls & young women 9 to 26 years of age. It can be given concomitantly with other vaccines.

*Gardasil™* should be administered intramuscularly in the deltoid muscle as 3 separate 0.5 ml doses according to the following schedule:  
 First dose:..... at elected date  
 Second dose:.... 2 months after the first dose  
 Third dose: ..... 6 months after the first dose.

**Gardasil™ is currently not a publicly funded vaccine. However, it should be made available on a cost-recovery-basis by public health units and health centres to individuals requesting it.**

**Attachments:** Product monograph & consumer information sheets.

This clinical practice is approved. \_\_\_\_\_  \_\_\_\_\_  
 (signature) (date) 23/11/06

Assistant Deputy Minister      
 Chief Medical Officer of Health      
 Director, Child & Family Services      
 Director, Adoptions